XTL Reports H1 2026 Loss of $899K; Discloses Psyga Deal, $1.5M Placement and New Derivative Claim
XTLB is trading near its 52-week low of $1.52 (1.3% above the low).
Summary
XTL posted a $899 thousand loss for H1 2026 and disclosed the full terms of its Psyga acquisition and June private placement, alongside a new shareholder motion seeking to file a derivative claim over the 2024 Social Proxy deal.
Key Events · Earnings and Guidance · XTLB
-
H1 2026 Loss of $899 Thousand
XTL reported a $899 thousand loss from continuing operations for the six months ended June 30, 2026, versus $1,186 thousand of income a year earlier. G&A expenses rose to $858 thousand from $510 thousand, driven by $145 thousand of share-based compensation and $151 thousand of directors' fees.
-
Psyga Acquisition Closed and Accounted For
The company acquired 83.4% of Psyga Bio for 492,082,705 ordinary shares plus milestone warrants, with total consideration of $3,534 thousand and $3,184 thousand allocated to goodwill. The shares were issued in August 2026, after the June 30 balance sheet date.
-
$1.5 Million Placement Priced at $2.70 per ADS
The June 29, 2026 private placement sold 555,555 ADSs at $2.70 each with Series A and B warrants and up to 555,556 contingent Series C warrants, plus a further $300 thousand round with two non-interested parties. The warrants are liability-classified and carried at $1,798 thousand at June 30, 2026.
-
Derivative Claim Motion Filed Over Social Proxy
On August 3, 2026 a shareholder asked the Tel Aviv-Jaffa District Court for permission to bring a derivative claim against the controlling shareholder and certain current and former directors and officers over the 2024 Social Proxy acquisition, estimating damages at approximately NIS 100 million for court-fee purposes. XTL says the motion is meritless and has recorded no provision.
Analysis · XTLB · Life Sciences
XTL's first detailed look at its post-Psyga balance sheet arrives with two items that change the risk picture. The company swung to a $899 thousand loss from $1,186 thousand of income a year earlier, and its equity cushion is thin: $2,632 thousand of total equity against $3,901 thousand of liabilities. The June 29 placement raised $1,500 thousand in gross proceeds at $2.70 per ADS, well above today's $1.54 price, and the warrants attached to it sit on the balance sheet as a $1,798 thousand liability that gets remeasured each period. Separately, a shareholder filed a motion on August 3, 2026 seeking court permission to bring a derivative suit against the controlling shareholder and certain directors and officers over the 2024 Social Proxy acquisition, with damages estimated at roughly NIS 100 million for court-fee purposes. XTL calls the motion meritless and has recorded no provision. Nasdaq compliance was regained on July 20, 2026, but the company is now inside a one-year monitoring window where a fresh equity-rule breach would go straight to a delist determination with no cure period.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XTLB was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $1.52 to $5.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.